These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 32019260)

  • 1. CD155: A Multi-Functional Molecule in Tumor Progression.
    Molfetta R; Zitti B; Lecce M; Milito ND; Stabile H; Fionda C; Cippitelli M; Gismondi A; Santoni A; Paolini R
    Int J Mol Sci; 2020 Jan; 21(3):. PubMed ID: 32019260
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD155, an onco-immunologic molecule in human tumors.
    Gao J; Zheng Q; Xin N; Wang W; Zhao C
    Cancer Sci; 2017 Oct; 108(10):1934-1938. PubMed ID: 28730595
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD155 and Its Receptors as Targets for Cancer Therapy.
    Paolini R; Molfetta R
    Int J Mol Sci; 2023 Aug; 24(16):. PubMed ID: 37629138
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor intrinsic and extrinsic immune functions of CD155.
    O'Donnell JS; Madore J; Li XY; Smyth MJ
    Semin Cancer Biol; 2020 Oct; 65():189-196. PubMed ID: 31883911
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Essential role of CD155 glycosylation in functional binding to DNAM-1 on natural killer cells.
    Tahara S; Okumura G; Matsuo T; Shibuya A; Shibuya K
    Int Immunol; 2024 Apr; 36(6):317-325. PubMed ID: 38289706
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DNAM-1 and the TIGIT/PVRIG/TACTILE Axis: Novel Immune Checkpoints for Natural Killer Cell-Based Cancer Immunotherapy.
    Sanchez-Correa B; Valhondo I; Hassouneh F; Lopez-Sejas N; Pera A; Bergua JM; Arcos MJ; Bañas H; Casas-Avilés I; Durán E; Alonso C; Solana R; Tarazona R
    Cancers (Basel); 2019 Jun; 11(6):. PubMed ID: 31234588
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Primary human tumor cells expressing CD155 impair tumor targeting by down-regulating DNAM-1 on NK cells.
    Carlsten M; Norell H; Bryceson YT; Poschke I; Schedvins K; Ljunggren HG; Kiessling R; Malmberg KJ
    J Immunol; 2009 Oct; 183(8):4921-30. PubMed ID: 19801517
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Laquinimod, a prototypic quinoline-3-carboxamide and aryl hydrocarbon receptor agonist, utilizes a CD155-mediated natural killer/dendritic cell interaction to suppress CNS autoimmunity.
    Ott M; Avendaño-Guzmán E; Ullrich E; Dreyer C; Strauss J; Harden M; Schön M; Schön MP; Bernhardt G; Stadelmann C; Wegner C; Brück W; Nessler S
    J Neuroinflammation; 2019 Feb; 16(1):49. PubMed ID: 30808363
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PVR (CD155) and Nectin-2 (CD112) as ligands of the human DNAM-1 (CD226) activating receptor: involvement in tumor cell lysis.
    Pende D; Bottino C; Castriconi R; Cantoni C; Marcenaro S; Rivera P; Spaggiari GM; Dondero A; Carnemolla B; Reymond N; Mingari MC; Lopez M; Moretta L; Moretta A
    Mol Immunol; 2005 Feb; 42(4):463-9. PubMed ID: 15607800
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of PVR (CD155) and Nectin-2 (CD112) as cell surface ligands for the human DNAM-1 (CD226) activating molecule.
    Bottino C; Castriconi R; Pende D; Rivera P; Nanni M; Carnemolla B; Cantoni C; Grassi J; Marcenaro S; Reymond N; Vitale M; Moretta L; Lopez M; Moretta A
    J Exp Med; 2003 Aug; 198(4):557-67. PubMed ID: 12913096
    [TBL]